Last Updated: November 16, 2026

Investigational Drug Information for LY3214996

« Back to Dashboard


What is the development status for investigational drug LY3214996?

LY3214996 is an investigational drug.

There have been 10 clinical trials for LY3214996. The most recent clinical trial was a Phase 1 trial, which was initiated on September 28th 2020.

The most common disease conditions in clinical trials are Pancreatic Neoplasms, Colorectal Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Eli Lilly and Company, Dana-Farber Cancer Institute, and Loxo Oncology, Inc.

There are nine US patents protecting this investigational drug and forty-two international patents.

Recent Clinical Trials for LY3214996
TitleSponsorPhase
Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant CancersLustgarten FoundationPhase 1
Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant CancersThe Netherlands Cancer InstitutePhase 1
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)Loxo Oncology, Inc.Phase 1

See all LY3214996 clinical trials

Clinical Trial Summary for LY3214996

Top disease conditions for LY3214996
Top clinical trial sponsors for LY3214996

See all LY3214996 clinical trials

US Patents for LY3214996

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LY3214996 ⤷  Start Trial ERK inhibitor and use thereof Betta Pharmaceuticals Co Ltd ⤷  Start Trial
LY3214996 ⤷  Start Trial Method for producing cardiomyocytes Kyoto Prefectural PUC , Kataoka Corp ⤷  Start Trial
LY3214996 ⤷  Start Trial Diacylglycerol kinase modulating compounds Carna Biosciences Inc , Gilead Sciences Inc ⤷  Start Trial
LY3214996 ⤷  Start Trial Methods for cancer detection and monitoring Natera Inc ⤷  Start Trial
LY3214996 ⤷  Start Trial Diacylglycerol kinase modulating compounds Carna Biosciences Inc , Gilead Sciences Inc ⤷  Start Trial
LY3214996 ⤷  Start Trial Heterocyclic compounds and uses thereof Kumquat Biosciences Inc ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for LY3214996

Drugname Country Document Number Estimated Expiration Related US Patent
LY3214996 Argentina AR102977 2034-12-22 ⤷  Start Trial
LY3214996 Australia AU2015369983 2034-12-22 ⤷  Start Trial
LY3214996 Brazil BR112017011130 2034-12-22 ⤷  Start Trial
LY3214996 Canada CA2966559 2034-12-22 ⤷  Start Trial
LY3214996 Chile CL2017001514 2034-12-22 ⤷  Start Trial
LY3214996 China CN107108648 2034-12-22 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.